Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —

Rhea-AI Summary

Exelixis, Inc. (NASDAQ: EXEL) announced that CEO Michael M. Morrissey, Ph.D., will deliver a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 PM ET. Investors can access the webcast via www.exelixis.com, under the News & Events section. A replay will be available for 30 days post-event. Exelixis is dedicated to developing innovative cancer therapies, with a portfolio that includes four commercially available products and a commitment to advancing its pipeline.

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 41^st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15pm ET / 5:15pm PT.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for at least 30 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX^® (cabozantinib), COMETRIQ^® (cabozantinib), COTELLIC^® (cobimetinib) and MINNEBRO^® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005704/en/

Investors Contact:

Varant Shirvanian

Associate Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

What date will Exelixis present at the J.P. Morgan Healthcare Conference?

Exelixis will present on January 9, 2023.

Who is presenting for Exelixis at the 2023 J.P. Morgan Healthcare Conference?

Michael M. Morrissey, Ph.D., the CEO of Exelixis, will present.

What time is Exelixis' presentation at the J.P. Morgan Healthcare Conference?

The presentation is scheduled for 8:15 PM ET.

How can I access the Exelixis presentation webcast?

You can access the webcast by visiting www.exelixis.com under the News & Events section.

Will there be a replay of the Exelixis presentation available?

Yes, a replay will be available for at least 30 days after the presentation.